Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cancer.
Helocyte has raised $3.2M in total funding. The most recent round was Grant. The last funding was announced in June 2023.
Helocyte's investors include SternAegis, National Cancer Institute.
Helocyte is headquartered in New York, United States.
Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cancer.
Helocyte is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Helocyte — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/helocyte. Accessed September 30, 2026.
VCBacked. (2023). Helocyte — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/helocyte
{{cite web |title=Helocyte — Funding & Investors |url=https://www.vcbacked.co/company/helocyte |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated